The clinical trial results are one of the two major catalysts that affect the stock price of a biotech company, and more so if it is a small/mid-cap stock.In this article, we will discuss the anticipated near-term milestones of Albireo Pharma Inc. (ALBO), Alnylam Pharmaceuticals Inc. (ALNY), Corbus Pharmaceuticals Holdings Inc. (CRBP), Mesoblast Limited (MESO) and Outlook Therapeutics (OTLK).
from RTT - Biotech https://ift.tt/3kUZmSW
via IFTTT
No comments:
Post a Comment